Business
COVID-19 BUSINESS IMPACT UPDATE
COVID-19 BUSINESS IMPACT UPDATE.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \n \n RNS Number : 1356I\n Angle PLC\n 31 March 2020\n \n \n \n \n \n \n \n \n For immediate release\n \n \n \n \n 31 March 2020\n \n \n \n \n \n \n \n \n ANGLE plc (\"the Company\")\n \n \n \n \n \n COVID-19 BUSINESS IMPACT UPDATE\n \n \n \n \n \n \n ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, provides an update in relation to the impact of the Coronavirus (COVID-19) pandemic on its business.\n \n \n \n \n \n ANGLE's operations and activities in the UK, Canada and the US have all been impacted by the COVID-19 pandemic and resulting Government directives. We take the health, safety and wellbeing of our staff, blood donors and the broader community very seriously. Following the \n UK Prime Minister's announcement on 23 March 2020 that UK citizens should only leave their homes for certain very limited purposes, we took the decision to temporarily cease operations at the ANGLE UK laboratories and offices. Throughout the medical device and diagnostic industry, the COVID-19 pandemic is severely disrupting clinical trials and research studies due to the temporary cessation of patient enrolment along with associated research activities at clinical sites. These extraordinary measures have been taken in order to allocate resources to healthcare systems and to seek to reduce the spread of COVID-19. \n \n \n \n \n \n As a response to the domestic and global COVID-19 situation, ANGLE has implemented its business continuity plan and can provide the following update on its ongoing clinical work.\n \n \n \n \n \n US Food and Drug Administration (FDA) Submission\n \n \n \n \n \n ANGLE has been following its stated plan and working flat out on the FDA De Novo Submission in metastatic breast cancer for the Parsortix® system. Although this work is very near completion, there are still a small number of analytical samples to be processed, which require healthy volunteer donor blood. The Prime Minister's announcement on 23 March resulted in the immediate loss of availability of healthy volunteer blood donors, which was a key factor in our decision to temporarily close our UK laboratory. \n \n \n \n \n \n Since the announcement by the UK Government on 23 March, the ANGLE team has investigated how the remaining analytical samples co...